本文選題：DPP-4抑制劑 + 二甲雙胍��； 參考：《天津醫(yī)科大學(xué)》2017年碩士論文

【摘要】：目的比較DPP-4抑制劑+二甲雙胍和其他降糖藥物+二甲雙胍治療2型糖尿病的療效和安全性。方法計(jì)算機(jī)檢索中文數(shù)據(jù)庫:中國知網(wǎng),萬方,維普和中國生物醫(yī)學(xué)文獻(xiàn)數(shù)據(jù)庫,英文數(shù)據(jù)庫:Pubmed,Embase和Cochrane Library,發(fā)表日期截止至2015年6月1日,根據(jù)納入排除標(biāo)準(zhǔn)對文獻(xiàn)進(jìn)行篩選和評價,用Rev-Man 5.3.5軟件對數(shù)據(jù)進(jìn)行分析。結(jié)果1.DPP-4抑制劑+二甲雙胍vs.磺脲類藥物(SUs)+二甲雙胍在降低糖化血紅蛋白(Hb A1c)方面兩組并無區(qū)別;在降低空腹血糖(FPG)方面SUs+二甲雙胍優(yōu)于DPP-4抑制劑+二甲雙胍,差異具有統(tǒng)計(jì)學(xué)意義;在不良反應(yīng)發(fā)生率,低血糖發(fā)生率和降低體重方面DPP-4抑制劑+二甲雙胍均優(yōu)于SUs+二甲雙胍,差異具有統(tǒng)計(jì)學(xué)意義。2.DPP-4抑制劑+二甲雙胍vs.噻唑烷二酮類藥物藥物(TZDs)+二甲雙胍在降低Hb A1c和FPG方面以及不良反應(yīng)發(fā)生率和低血糖發(fā)生率方面兩組均沒有差別;在降低體重方面DPP-4抑制劑+二甲雙胍優(yōu)于TZDs+二甲雙胍,差異具有統(tǒng)計(jì)學(xué)意義。3.DPP-4抑制劑+二甲雙胍vs.GLP-1受體激動劑+二甲雙胍在降低Hb A1c,FPG和體重方面,GLP-1受體激動劑+二甲雙胍均優(yōu)于DPP-4抑制劑+二甲雙胍,差異具有統(tǒng)計(jì)學(xué)意義;在不良反應(yīng)發(fā)生率方面DPP-4抑制劑+二甲雙胍低于GLP-1抑制劑受體激動劑,差異具有統(tǒng)計(jì)學(xué)意義;在低血糖發(fā)生率方面,兩組并無差別。4.DPP-4抑制劑+二甲雙胍vs.SGLT-2抑制劑+二甲雙胍在降低FPG和體重方面SGLT-2抑制劑+二甲雙胍優(yōu)于DPP-4抑制劑+二甲雙胍,差異具有統(tǒng)計(jì)學(xué)意義;在降低Hb A1c方面和不良反應(yīng)發(fā)生率,低血糖發(fā)生率方面,兩組并無差別。結(jié)論在控制血糖方面,DPP-4抑制劑+二甲雙胍療效僅劣于GLP-1受體激動劑+二甲雙胍(P0.05),與其他三種藥物與二甲雙胍的組合并無差別(P0.05);可以輕微的降低體重;安全性良好,不良反應(yīng)和低血糖發(fā)生率低,可以作為治療2型糖尿病的一種有效療法。
[Abstract]:Objective to compare the efficacy and safety of DPP-4 inhibitor metformin and other hypoglycemic drugs metformin in the treatment of type 2 diabetes. Methods Chinese databases were searched by computer: China Zhiwang, Wanfang, Weipu and Chinese Biomedical Literature Database, English Database: Pubmed Embase and Cochrane Library. The publication date was until June 1, 2015. According to the exclusion criteria, the literature was screened and evaluated, and the data were analyzed by Rev-Man 5.3.5 software. Results 1.DPP-4 inhibitor metformin vs. There was no difference between the two groups in reducing HbA1c of glycosylated hemoglobin (HbA1c), SUs metformin was superior to DPP-4 inhibitor metformin in lowering fasting blood glucose, the difference was statistically significant, and the incidence of adverse reactions was higher than that of DPP-4 inhibitor metformin. The incidence of hypoglycemia and weight loss of DPP-4 inhibitor metformin were higher than that of SUs metformin, and the difference was statistically significant. There was no difference between the two groups in reducing HbA1c and FPG, the incidence of adverse reactions and hypoglycemia, and the DPP-4 inhibitor metformin was superior to TZDs metformin in reducing body weight. The difference was statistically significant. 3. Metformin, an agonist of metformin vs.GLP-1 receptor with DPP-4 inhibitor, was superior to DPP-4 inhibitor metformin in reducing HbA1cFPG and body weight, and the difference was statistically significant. The incidence of adverse reactions of DPP-4 inhibitor metformin was significantly lower than that of GLP-1 inhibitor receptor agonist, and the incidence of hypoglycemia was significantly lower than that of GLP-1 inhibitor receptor agonist. There was no difference between the two groups. 4. DPP-4 inhibitor metformin vs.SGLT-2 inhibitor metformin was superior to DPP-4 inhibitor metformin in reducing FPG and body weight, and the difference was statistically significant. There was no difference between the two groups in reducing HB A 1c, adverse reactions and hypoglycemia. Conclusion the effect of metformin, a DPP-4 inhibitor on blood glucose control, is only inferior to that of GLP-1 receptor agonist metformin P0.05, and has no difference with the combination of other three drugs with metformin. Low incidence of adverse reactions and hypoglycemia can be used as an effective treatment for type 2 diabetes.
【學(xué)位授予單位】：天津醫(yī)科大學(xué)
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2017
【分類號】：R587.1

【參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 蓋克克;段蓉;李正翔;;二肽基肽酶-4抑制劑臨床應(yīng)用研究進(jìn)展[J];中國醫(yī)院藥學(xué)雜志;2016年17期

2 梁勇前;劉湘茹;胡德龍;羅蓓;;二甲雙胍聯(lián)合西格列汀或吡格列酮對肥胖型2型糖尿病的療效比較[J];北方藥學(xué);2015年05期

3 楊繼琰;何新朝;;二甲雙胍聯(lián)合磷酸西格列汀治療2型糖尿病的療效[J];臨床合理用藥雜志;2015年12期

4 范曉霞;劉學(xué)良;羅瑋;姚勇利;;利拉魯肽與沙格列汀對肥胖2型糖尿病患者療效及安全性的臨床觀察[J];中國糖尿病雜志;2015年04期

5 羅晶;張紹維;丁麗;趙文洲;;格列美脲或西格列汀聯(lián)合二甲雙胍對初診T2DM患者胰島功能影響的對比研究[J];遼寧醫(yī)學(xué)雜志;2015年02期

6 柴杰;李海燕;陳淑娟;;西格列汀聯(lián)合二甲雙胍治療初診2型糖尿病的臨床研究[J];中國實(shí)用醫(yī)刊;2015年05期

7 許仕超;張華麗;黎偉文;陳曉銘;武革;;西格列汀聯(lián)合二甲雙胍治療2型糖尿病的療效觀察[J];當(dāng)代醫(yī)學(xué);2015年03期

8 黃戀川;林墾;王言;葉曉平;;安立澤聯(lián)合二甲雙胍治療2型糖尿病的療效及安全性觀察[J];華南國防醫(yī)學(xué)雜志;2014年10期

9 鄭玉卿;于永波;李要京;侯曉明;李強(qiáng);;二甲雙胍分別聯(lián)合艾塞那肽及沙格列汀治療2型糖尿病的療效及HbA1c達(dá)標(biāo)率比較[J];臨床合理用藥雜志;2014年28期

10 陳彬;張星光;李艷玲;武晉曉;趙晶;呂肖鋒;;利拉魯肽與西格列汀分別聯(lián)合二甲雙胍治療2型糖尿病效果觀察[J];解放軍醫(yī)藥雜志;2014年09期

，

本文編號：1896932